1,563 followers
@NICEComms @ERSpublications @LondonAsthma Dupilumab is a mAb targeted against the α subunit of the IL-4 receptor, a ligand for both IL-4 and IL-13. It was initially rejected by @nicecomms but licenced in 2021 for #asthma patients with type 2 inflammation h